ProKidney Corp. (PROK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProKidney Corp. (PROK) has a cash flow conversion efficiency ratio of -0.181x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.37 Million) by net assets ($222.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PROK market cap for the company's overall valuation and market capitalisation.
ProKidney Corp. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how ProKidney Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
ProKidney Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProKidney Corp. ranked by their cash flow conversion efficiency. See PROK debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Source Capital Closed Fund
NYSE:SOR
|
-0.093x |
|
Hangzhou Juheshun New Material Co Ltd
SHG:605166
|
-0.008x |
|
Asia Cuanon Tech (Shanghai)
SHG:603378
|
-0.615x |
|
Seoul Semiconductor Co. Ltd
KQ:046890
|
0.067x |
|
Shenzhen Liantronics
SHE:300269
|
0.097x |
|
Dongwoon Anatech Co Ltd
KQ:094170
|
0.063x |
|
Shandong Longda Meat Foodstuff Co Ltd
SHE:002726
|
-0.183x |
|
Dagang Nexchange Bhd
KLSE:4456
|
0.009x |
Annual Cash Flow Conversion Efficiency for ProKidney Corp. (2019–2025)
The table below shows the annual cash flow conversion efficiency of ProKidney Corp. from 2019 to 2025. View PROK stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $300.79 Million | $-120.12 Million | -0.399x | -26.94% |
| 2024-12-31 | $401.64 Million | $-126.35 Million | -0.315x | -36.68% |
| 2023-12-31 | $391.34 Million | $-90.07 Million | -0.230x | -50.76% |
| 2022-12-31 | $504.94 Million | $-77.09 Million | -0.153x | +91.83% |
| 2021-12-31 | $26.92 Million | $-50.30 Million | -1.869x | +26.80% |
| 2020-12-31 | $9.86 Million | $-25.18 Million | -2.553x | -52690.69% |
| 2019-12-31 | $15.88 Million | $-76.81K | -0.005x | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more